Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy.
about
Targeting Protein Kinase C Downstream of Growth Factor and Adhesion SignallingThe C-terminal V5 domain of Protein Kinase Cα is intrinsically disordered, with propensity to associate with a membrane mimeticProtein quality control disruption by PKCβII in heart failure; rescue by the selective PKCβII inhibitor, βIIV5-3Oxidative Stress-Induced Afterdepolarizations and Protein Kinase C SignalingInterleukin-1β reduces L-type Ca2+ current through protein kinase Cϵ activation in mouse heart.Aldehyde dehydrogenase 2 activation in heart failure restores mitochondrial function and improves ventricular function and remodelling.Aldehydic load and aldehyde dehydrogenase 2 profile during the progression of post-myocardial infarction cardiomyopathy: benefits of Alda-1Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure.Correlation of Lower Concentrations of Hydrogen Sulfide with Activation of Protein Kinase CβII in Uremic Accelerated Atherosclerosis PatientsAgonist activated PKCβII translocation and modulation of cardiac myocyte contractile function.Protein kinase C, an elusive therapeutic target?Tamoxifen use for the management of mania: a review of current preclinical evidence.Increased clearance of reactive aldehydes and damaged proteins in hypertension-induced compensated cardiac hypertrophy: impact of exercise training.Ischemia/Reperfusion-Induced Translocation of PKCβII to Mitochondria as an Important Mediator of a Protective Signaling Mechanism in an Ischemia-Resistant Region of the HippocampusResearch advances in kinase enzymes and inhibitors for cardiovascular disease treatment.Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders.Evolving Mechanisms of Vascular Smooth Muscle Contraction Highlight Key Targets in Vascular Disease.
P2860
Q26799902-83B1D6FD-BD66-46E8-A1FD-E98D52F3513DQ28533712-250D4F04-1FC0-444A-8E3B-9287620438E0Q28730834-9BCD70D0-33FE-4892-B16D-1CA3E8B3EA4BQ33624234-8AD081E7-6298-4545-B028-29F0F3C2DA4CQ34070335-9C76477F-9C0D-48E5-BCD7-29A80FFC950DQ34137983-6F3B27F0-9DF2-4A66-BD54-E038DA4FD17DQ35510238-A044C80A-C0EA-4E5E-875C-A68976700C4BQ36185429-66F10844-1D61-4BB6-A38B-2ED68A10348EQ36523249-FDE3DF58-238D-4D2D-8431-FB9983AC6280Q36920937-4CAC5B89-BE37-49E3-BBD5-FEBB654F905AQ37141320-39D4BC38-26B4-42A6-BB22-17A16F595C60Q38179926-DAA10E96-507A-43D1-8BA6-1504DB0A3CDCQ39994155-C8178A39-E6B4-4B1D-A644-180541552104Q41109150-E1C2ABD1-0A15-4CA8-BB21-6B4647733E75Q47121794-D134636A-3628-4836-AD3D-430598F5D7DAQ47131231-56F53D30-414F-41B6-A473-195679FE0067Q49923465-5D1E2168-B592-43E8-8A32-82CAA2B7D9AF
P2860
Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy.
@ast
Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy.
@en
type
label
Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy.
@ast
Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy.
@en
prefLabel
Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy.
@ast
Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy.
@en
P2093
P2860
P1476
Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy.
@en
P2093
Daniel Bernstein
Eric N Churchill
Giovanni Fajardo
Grant Budas
Julio C B Ferreira
Marie-Helene Disatnik
Patricia C Brum
Suresh S Palaniyandi
Tomoyoshi Koyanagi
P2860
P304
P356
10.1016/J.YJMCC.2011.08.025
P577
2011-09-02T00:00:00Z